₹-0.41
(Market cap
₹27 Cr
Recently Viewed
Clear AllMarket cap
₹27 Cr
Revenue (TTM)
₹765 Cr
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-278 Cr
ROE
7.4 %
ROCE
9.8 %
Industry P/E
45.59
EV/EBITDA
12.2
Debt to Equity
0.3
Book Value
₹--
EPS
₹-13.2
Face value
10
Shares outstanding
34,066,667
CFO
₹551.70 Cr
EBITDA
₹1,676.79 Cr
Net Profit
₹1,330.21 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Plethico Pharmaceuticals
| -39.8 | -5.6 | -21.9 | -70.6 | -67.1 | -53.2 | -29.9 |
|
BSE Sensex*
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
|
BSE Healthcare#
| -1.9 | -1.8 | -2.4 | 7.7 | 24.3 | 13.4 | 10.8 |
|
Company
|
2015
|
2014
|
|---|---|---|
|
Plethico Pharmaceuticals
| -68.6 | -19.6 |
|
BSE Sensex
| -5.0 | 29.9 |
|
BSE Healthcare
| 15.1 | 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Plethico Pharmaceuticals
|
7.9 | 27.1 | 765.1 | -277.7 | 7.2 | -3.1 | -- | 0.0 |
| 2,362.2 | 19,351.5 | 1,215.1 | 284.8 | 28.7 | 21.1 | 67.4 | 12.7 | |
| 724.2 | 14,230.2 | 7,266.8 | 627.5 | 11.9 | 12.6 | 22.6 | 2.6 | |
| 632.0 | 15,658.3 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.7 | 3.5 | |
| 890.8 | 14,203.9 | 7,918.4 | 429.9 | 10.7 | 7.2 | 32.8 | 2.1 | |
| 1,104.2 | 19,771.9 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.7 | 2.2 | |
| 1,438.9 | 16,477.6 | 1,419.3 | 20.1 | 8.4 | 0.5 | 819.7 | 2.8 | |
| 146.0 | 19,420.3 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 404.7 | 16,309.0 | 3,720.2 | 352.1 | 13.7 | 8.2 | 46.3 | 3.4 | |
| 1,343.8 | 21,839.8 | 3,151.0 | -10.0 | 8.4 | 2.5 | 992.7 | 4.7 |
Stocks are not always the best option
5 min read•By Research Desk
2 min read•By Research Desk
Manufacture of allopathic pharmaceutical preparations
Incorporated
1991
Chairman
Shashikant Patel
Managing Director
Shashikant Patel
Headquarters
Indore Dist, Madhya Pradesh
Website
Looking for more details about Plethico Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsShareholding for the Period Ended June 30, 2016
25-Jul-2016Shareholding for the Period Ended March 31, 2016
21-Apr-2016Shareholding Pattern For September 30, 2015
23-Mar-2016Shareholding Pattern For June 30, 2015
23-Mar-2016
The share price of Plethico Pharmaceuticals Ltd is ₹7.94 (BSE) and ₹21.55 (NSE) as of 13-Jun-2016 IST. Plethico Pharmaceuticals Ltd has given a return of -67.06% in the last 3 years.
Since, TTM earnings of Plethico Pharmaceuticals Ltd is negative, P/E ratio is not available.
The P/B ratio of Plethico Pharmaceuticals Ltd is 0.02 times as on 13-Jun-2016, a 99 discount to its peers’ median range of 3.19 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2012
|
10.26
|
0.76
|
|
2011
|
11.70
|
0.90
|
|
2010
|
5.44
|
1.18
|
|
2009
|
6.42
|
1.46
|
|
2008
|
2.16
|
0.57
|
The 52-week high and low of Plethico Pharmaceuticals Ltd are Rs -- and Rs -- as of 10-Apr-2026.
Plethico Pharmaceuticals Ltd has a market capitalisation of ₹ 27 Cr as on 13-Jun-2016. As per SEBI classification, it is a company.
Before investing in Plethico Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.